Wall Street Zen Upgrades Biomea Fusion (NASDAQ:BMEA) to “Hold”

Biomea Fusion (NASDAQ:BMEA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other equities analysts have also issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Biomea Fusion in a research note on Wednesday. Citigroup boosted their price objective on shares of Biomea Fusion from $6.00 to $7.00 and gave the company a “buy” rating in a report on Friday. Rodman & Renshaw assumed coverage on shares of Biomea Fusion in a research report on Tuesday, January 13th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biomea Fusion in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.75.

Biomea Fusion Stock Performance

Shares of Biomea Fusion stock opened at $1.32 on Friday. The stock has a 50 day moving average of $1.29 and a 200 day moving average of $1.42. The firm has a market capitalization of $95.44 million, a price-to-earnings ratio of -1.01 and a beta of -0.20. Biomea Fusion has a fifty-two week low of $0.87 and a fifty-two week high of $3.08.

Institutional Investors Weigh In On Biomea Fusion

Institutional investors and hedge funds have recently modified their holdings of the company. Scientech Research LLC acquired a new position in Biomea Fusion during the 3rd quarter worth about $25,000. Engineers Gate Manager LP acquired a new position in Biomea Fusion in the 2nd quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Biomea Fusion during the third quarter worth about $32,000. Millennium Management LLC increased its stake in Biomea Fusion by 156.7% during the fourth quarter. Millennium Management LLC now owns 25,677 shares of the company’s stock worth $32,000 after purchasing an additional 15,675 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Biomea Fusion during the third quarter worth about $39,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Key Stories Impacting Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Citigroup raised its price target on BMEA from $6.00 to $7.00 and reiterated a “buy” rating — the new target implies substantial upside versus the current share level. Read More.
• Positive Sentiment: HC Wainwright published a set of updated EPS forecasts (Q1–Q4 2026 and FY2026–FY2028) and materially lifted its multi-year loss estimates (FY2026 from ($1.37) to ($0.57); FY2027 to ($0.64); FY2028 to ($0.78)), signaling the firm expects smaller losses and improving financials over time. The report also lists per-quarter EPS expectations for 2026. Read More.
• Positive Sentiment: D. Boral Capital initiated/maintained a buy rating on Biomea Fusion, adding another independent positive analyst voice. Read More.
• Positive Sentiment: Recent coverage highlights continued strong analyst sentiment driven by encouraging diabetes trial results, supporting the investment case for BMEA’s pipeline upside. Read More.
• Neutral Sentiment: Despite the positive analyst action and trial commentary, the stock is trading lower today — likely a short-term reaction (profit-taking, low liquidity, or risk-off flows common in small-cap biotech) rather than a reversal of analyst views. Monitor trading volume and upcoming clinical or corporate catalysts for signs of follow-through.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.